Efficacy of Sijunzi Decoction combined with Xuefu Zhuyu Decoction in treating patients with qi deficiency and blood stasis syndrome after surgery and chemotherapy for non-small cell lung cancer,and its effects on the levels of bFGF,TGF-β1,VEGF,CD3+,and CD4
Objective To investigate the efficacy of Sijunzi Decoction combined with Xuefu Zhuyu Decoction in treating patients with qi deficiency and blood stasis syndrome following surgery and chemotherapy for non-small cell lung cancer,and to examine its effects on the levels of basic fibroblast growth factor,transforming growth factor-beta1(TGF-β1),vascular endothelial growth factor(VEGF),CD3+,CD4+,and the CD4+/CD8+ratio.Methods A total of 86 patients with qi deficiency and blood stasis syndrome after surgery and chemotherapy for non-small cell lung cancer who received treatment at Ankang Hospital of Traditional Chinese Medicine between June 2020 and June 2023 were included in this study.Using a randomized controlled trial design,the 86 patients were divided into a control group and an observation group,with 43 patients in each group,based on a random number table method.Both groups received chemotherapy with Vinorelbine and Cisplatin after surgery.The control group received conventional symptomatic supportive treatment,while the observation group was additionally treated with Sijunzi Decoction combined with Xuefu Zhuyu Decoction orally.The two groups were compared in terms of traditional Chinese medicine syndrome scores and clinical efficacy during the 1st,2nd,and 4th cycles of treatment,as well as the Revised Piper Fatigue Scale and Quality of Life scores.Additionally,the levels of bFGF,TGF-β1,and VEGF,CD3+,CD4+,and the CD4+/CD8+ratio were measured before and after treatment.The incidence of adverse reactions was also recorded.Results The observation group showed significantly lower traditional Chinese medicine syndrome scores during the 1st,2nd,and 4th cycles of treatment compared with the control group[(24.05±2.82)points vs.(28.11±3.16)points,(18.24±2.05)points vs.(22.52±2.45)points,(14.18±1.46)points vs.(18.67±2.13)points,t=3.86,4.48,4.50,all P＜0.05].After treatment,the Revised Piper Fatigue Scale score in the observation group was significantly lower than that in the control group(t=8.86,P＜0.05),while the Quality of Life score in the observation group was significantly higher than that in the control group(t=7.42,P＜0.05).Moreover,the levels of bFGF,TGF-β1,and VEGF in the observation group were significantly lower than those in the control group(t=5.26,8.15,5.86,all P＜0.05).Additionally,the levels of CD3+,CD4+,and the CD4+/CD8+ratio in the observation group were significantly higher than those in the control group(t=5.15,3.76,3.15,all P＜0.05).The incidence of adverse reactions in the observation group was 6.98％(3/43),which was significantly lower than 18.60％(8/43)in the control group(x2=4.48,P=0.021).Conclusion In patients with qi deficiency and blood stasis syndrome following surgery and chemotherapy for non-small cell lung cancer,the addition of Sijunzi Decoction combined with Xuefu Zhuyu Decoction can significantly alleviate clinical symptoms and fatigue,improve quality of life,and demonstrate high safety.This combined treatment effectively regulates the levels of TGF-β1,VEGF,and bFGF in patients with lung cancer,inhibits angiogenesis,and exerts anti-tumor effects.Furthermore,it modulates the expression of T cell subsets and enhances immune function.
Lung neoplasmsPneumonectomyImmunityQuality of lifeComparative effectiveness researchSijunzi tangHematopoietic blood stasis-expelling tang
NETL
NSTL
万方数据
